Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.4/2088 |
Resumo: | PURPOSE: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. PATIENTS AND METHODS: Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. RESULTS: Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS centres; 266 patients were eligible. Fifty (18.7%) had metastases at diagnosis. Of 216 patients with localised disease, 211 (98%) underwent surgery (R0 = 70.6%, R1 = 27%). Five-year overall survival (OS) for all 266 patients was 47% (95% CI 40-54%). Five-year OS for metastatic patients was 27% (95% CI 13-41%). In the analysis restricted to the 211 localised patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI 44-59%) and 5-year disease-free survival (DFS) was 43% (95% CI 35-51%). One hundred twenty-one patients (57.3%) received adjuvant or neoadjuvant chemotherapy and 80 patients (37.9%) received radiotherapy. A favourable trend was seen for osteosarcoma-type chemotherapy versus soft tissue sarcoma-type (doxorubicin ± ifosfamide) regimens. For the 211 patients in complete remission after surgery, patient age, tumour size, margins and chemotherapy were positive prognostic factors for DFS and OS by univariate analysis. At multivariate analysis, patient age (≤40 years versus >40 years) (P = 0.05), tumour size (P = 0.0001) and receipt of chemotherapy (P = 0.006) were statistically significant prognostic factors for survival. CONCLUSION: Patient age and tumour size are factors influencing ESOS prognosis. Higher survival was observed in patients who received perioperative chemotherapy with a trend in favour of multiagent osteosarcoma-type regimen which included doxorubicin, ifosfamide and cisplatin. |
id |
RCAP_2c34237f1cc6ceed32c85705cae42a7d |
---|---|
oai_identifier_str |
oai:rihuc.huc.min-saude.pt:10400.4/2088 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patientsQuimiorradioterapiaOsteosarcomaNeoplasias dos Tecidos MolesEuropaPURPOSE: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. PATIENTS AND METHODS: Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. RESULTS: Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS centres; 266 patients were eligible. Fifty (18.7%) had metastases at diagnosis. Of 216 patients with localised disease, 211 (98%) underwent surgery (R0 = 70.6%, R1 = 27%). Five-year overall survival (OS) for all 266 patients was 47% (95% CI 40-54%). Five-year OS for metastatic patients was 27% (95% CI 13-41%). In the analysis restricted to the 211 localised patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI 44-59%) and 5-year disease-free survival (DFS) was 43% (95% CI 35-51%). One hundred twenty-one patients (57.3%) received adjuvant or neoadjuvant chemotherapy and 80 patients (37.9%) received radiotherapy. A favourable trend was seen for osteosarcoma-type chemotherapy versus soft tissue sarcoma-type (doxorubicin ± ifosfamide) regimens. For the 211 patients in complete remission after surgery, patient age, tumour size, margins and chemotherapy were positive prognostic factors for DFS and OS by univariate analysis. At multivariate analysis, patient age (≤40 years versus >40 years) (P = 0.05), tumour size (P = 0.0001) and receipt of chemotherapy (P = 0.006) were statistically significant prognostic factors for survival. CONCLUSION: Patient age and tumour size are factors influencing ESOS prognosis. Higher survival was observed in patients who received perioperative chemotherapy with a trend in favour of multiagent osteosarcoma-type regimen which included doxorubicin, ifosfamide and cisplatin.RIHUCLonghi, ABielack, SSGrimer, RWhelan, JWindhager, RLeithner, AGronchi, ABiau, DJutte, PKrieg, AHKlenke, FMGrignani, GDonati, DMCapanna, RCasanova, JGerrand, CBisogno, GHecker-Nolting, SDe Lisa, MD'Ambrosio, LWillegger, MScoccianti, GFerrari, S2017-09-01T10:28:11Z2017-032017-03-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/2088engEur J Cancer. 2017 Mar;74:9-1610.1016/j.ejca.2016.12.016info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-11T14:23:24Zoai:rihuc.huc.min-saude.pt:10400.4/2088Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:04:33.629458Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients |
title |
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients |
spellingShingle |
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients Longhi, A Quimiorradioterapia Osteosarcoma Neoplasias dos Tecidos Moles Europa |
title_short |
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients |
title_full |
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients |
title_fullStr |
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients |
title_full_unstemmed |
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients |
title_sort |
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients |
author |
Longhi, A |
author_facet |
Longhi, A Bielack, SS Grimer, R Whelan, J Windhager, R Leithner, A Gronchi, A Biau, D Jutte, P Krieg, AH Klenke, FM Grignani, G Donati, DM Capanna, R Casanova, J Gerrand, C Bisogno, G Hecker-Nolting, S De Lisa, M D'Ambrosio, L Willegger, M Scoccianti, G Ferrari, S |
author_role |
author |
author2 |
Bielack, SS Grimer, R Whelan, J Windhager, R Leithner, A Gronchi, A Biau, D Jutte, P Krieg, AH Klenke, FM Grignani, G Donati, DM Capanna, R Casanova, J Gerrand, C Bisogno, G Hecker-Nolting, S De Lisa, M D'Ambrosio, L Willegger, M Scoccianti, G Ferrari, S |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
RIHUC |
dc.contributor.author.fl_str_mv |
Longhi, A Bielack, SS Grimer, R Whelan, J Windhager, R Leithner, A Gronchi, A Biau, D Jutte, P Krieg, AH Klenke, FM Grignani, G Donati, DM Capanna, R Casanova, J Gerrand, C Bisogno, G Hecker-Nolting, S De Lisa, M D'Ambrosio, L Willegger, M Scoccianti, G Ferrari, S |
dc.subject.por.fl_str_mv |
Quimiorradioterapia Osteosarcoma Neoplasias dos Tecidos Moles Europa |
topic |
Quimiorradioterapia Osteosarcoma Neoplasias dos Tecidos Moles Europa |
description |
PURPOSE: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. PATIENTS AND METHODS: Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. RESULTS: Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS centres; 266 patients were eligible. Fifty (18.7%) had metastases at diagnosis. Of 216 patients with localised disease, 211 (98%) underwent surgery (R0 = 70.6%, R1 = 27%). Five-year overall survival (OS) for all 266 patients was 47% (95% CI 40-54%). Five-year OS for metastatic patients was 27% (95% CI 13-41%). In the analysis restricted to the 211 localised patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI 44-59%) and 5-year disease-free survival (DFS) was 43% (95% CI 35-51%). One hundred twenty-one patients (57.3%) received adjuvant or neoadjuvant chemotherapy and 80 patients (37.9%) received radiotherapy. A favourable trend was seen for osteosarcoma-type chemotherapy versus soft tissue sarcoma-type (doxorubicin ± ifosfamide) regimens. For the 211 patients in complete remission after surgery, patient age, tumour size, margins and chemotherapy were positive prognostic factors for DFS and OS by univariate analysis. At multivariate analysis, patient age (≤40 years versus >40 years) (P = 0.05), tumour size (P = 0.0001) and receipt of chemotherapy (P = 0.006) were statistically significant prognostic factors for survival. CONCLUSION: Patient age and tumour size are factors influencing ESOS prognosis. Higher survival was observed in patients who received perioperative chemotherapy with a trend in favour of multiagent osteosarcoma-type regimen which included doxorubicin, ifosfamide and cisplatin. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-09-01T10:28:11Z 2017-03 2017-03-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.4/2088 |
url |
http://hdl.handle.net/10400.4/2088 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Eur J Cancer. 2017 Mar;74:9-16 10.1016/j.ejca.2016.12.016 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131707897544704 |